Skip to main content

Table 1 Clinicopathological characteristics of recurrent pancreatic cancer patients with sarcopenia and without sarcopenia

From: Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study

Characteristics Sarcopenia group (n = 65) Non-sarcopenia group (n = 9) P value
Age at time of recurrence, year, median (range) 73.0 (44–85) 68.0 (53–80) 0.529
Sex, male (n, %) 44 (67.7%) 5 (55.6%) 0.476
Body mass index at the time of recurrence, median (range), kg/m2 18.9 (13.3–26.8) 23.4 (19.3–27.9) < 0.001
Primary tumor location (pancreatic head, %) 42 (64.6%) 6 (66.7%) 1.000
Primary tumor size, median (range), mm 28.0 (5–60) 30.0 (25–35) 0.466
Lymph node involvement (present, %) 45 (69.2%) 7 (77.8%) 0.716
Histological grading (G1a, %) 30 (46.2%) 6 (66.7%) 0.302
Time to recurrence after pancreatectomy (< 12 months, %) 25 (38.5%) 5 (55.6%) 0.471
Lymphatic vessel invasion (present, %) 23 (35.9%) 7 (77.8%) 0.027
Blood vessel invasion (present, %) 27 (41.5%) 6 (66.7%) 0.176
Perineural invasion (present, %) 9 (13.8%) 2 (22.2%) 0.615
Initial site of recurrence (distant, %) 41 (63.1%) 5 (55.6%) 0.722
Chemotherapy after recurrence (present, %) 49 (75.4%) 8 (88.9%) 0.675
Neutrophil-lymphocyte ratio, median (range) 1.94 (0.36–18.60) 1.62 (0.26–2.63) 0.378
Serum CA19-9 levels at time of recurrence, median (range), U/ml 206.5 (0.1–20,460) 92.1 (10.2–1843) 0.669
  1. Continuous variables are expressed as the median and range
  2. CA19-9 carbohydrate antigen 19-9
  3. aG1, well-differentiated